Literature DB >> 12194381

Risks and benefits of DNA testing for neurogenetic disorders.

T D Bird1.   

Abstract

DNA testing for mutations in genes causing neurogenetic disorders is becoming a common practice in clinical neurology. The tests are highly sensitive and specific. They are especially valuable in establishing diagnoses in symptomatic patients. These DNA tests are also used in asymptomatic persons at risk for genetic diseases who wish to determine whether or not they have inherited an abnormal gene. There are risks and benefits to such asymptomatic, predictive testing. A number of complex issues need to be considered including precipitation of depression, prenatal diagnosis and testing of children, impact on insurance and employment, legal aspects, possible third-party coercion, and an understanding of each test's limitations. Therefore, these DNA tests need to be used with careful clinical judgment and in the context of each individual patient and family.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 12194381     DOI: 10.1055/s-2008-1040841

Source DB:  PubMed          Journal:  Semin Neurol        ISSN: 0271-8235            Impact factor:   3.420


  4 in total

1.  Genetic counseling and testing for FSHD (facioscapulohumeral muscular dystrophy) in the Israeli population.

Authors:  Miri Yanoov-Sharav; Esther Leshinsky-Silver; Sarit Cohen; Chana Vinkler; Marina Michelson; Tally Lerman-Sagie; Mira Ginzberg; Menahem Sadeh; Dorit Lev
Journal:  J Genet Couns       Date:  2011-11-23       Impact factor: 2.537

2.  The perceived advantages and disadvantages of presymptomatic testing for Machado-Joseph disease: development of a new self-response inventory.

Authors:  Luísa Rolim; José A Zagalo-Cardoso; Constança Paúl; Jorge Sequeiros; Manuela Fleming
Journal:  J Genet Couns       Date:  2006-09-27       Impact factor: 2.537

3.  A survey of attitudes toward clinical trials and genetic disclosure in autosomal dominant Alzheimer's disease.

Authors:  Joshua D Grill; Randall J Bateman; Virginia Buckles; Angela Oliver; John C Morris; Colin L Masters; William E Klunk; John M Ringman
Journal:  Alzheimers Res Ther       Date:  2015-07-22       Impact factor: 6.982

Review 4.  Genetic counseling and testing practices for late-onset neurodegenerative disease: a systematic review.

Authors:  Ashley Crook; Chris Jacobs; Toby Newton-John; Rosie O'Shea; Alison McEwen
Journal:  J Neurol       Date:  2021-03-01       Impact factor: 6.682

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.